ABP 692 (ocrelizumab biosimilar)
/ Amgen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 03, 2025
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
(clinicaltrials.gov)
- P3 | N=444 | Recruiting | Sponsor: Amgen | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Multiple Sclerosis
1 to 1
Of
1
Go to page
1